Full-Time

Senior Quality Control Analyst

Microbiology

Confirmed live in the last 24 hours

Cellares

Cellares

201-500 employees

Develops and manufactures cell therapies

Compensation Overview

$90k - $210k/yr

Senior

Bridgewater Township, NJ, USA

Candidates must be able to commute to Bridgewater, New Jersey.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • B.S. degree in a science discipline required, or comparable experience
  • 5+ years of experience in cGMP or cGxP at an operational level supporting manufacturing in a pharmaceutical or biotech environment
  • Prior experience with EMPQ, Environmental Monitoring and microbiological assays (endotoxin, sterility)
  • Familiarity with rapid microbiology technology such as BAC-T, Nexgen-MCS is highly preferred
  • Sterility and endotoxin method qualification and transfer experience is highly preferred
  • Good adherence with current Good Manufacturing Practices (cGMP), ISO regulations (ISO 14644), USP chapters, FDA regulations and understanding of 21 CFR, USP, EP and FDA microbiology testing requirements
  • Experience in participating in audits and providing audit requests (internal and external including regulatory inspections)
  • Deep understanding of contamination control and aseptic processes, Knowledge of cleanroom classifications and requirements (ISO 5-8), ability to work in a cleanroom environment and adhere to gowning protocols
  • Must have excellent verbal, written, interpersonal, and organizational and communication skills
  • Must be able to commute to Bridgewater, New Jersey
  • Excellent verbal, written, organizational, presentation and interpersonal skills
  • Self-awareness, integrity, authenticity, and a growth mindset
Responsibilities
  • Responsible for performing microbiological testing of raw materials and cell therapy products in accordance with organization’s policies and SOPs
  • Serve as a deputy for the QC Microbiology Manager during absences, ensuring continuity of operations and decision-making, flexibility to handle additional responsibilities and dynamic situations
  • Responsible for performing routine and non-routine microbiology testing such as B&F and sterility test, bioburden testing, growth promotion testing of purchased media (iNST & iAST bottles, TSA RODAC and Settle plates, etc.) bacterial endotoxin method development/verification and routine testing, gram stain, microbial readings, investigational testing
  • Ability to work effectively within controlled environments under cGMP regulations, responsible for overseeing and maintaining gowning qualification program
  • Participate in aseptic process simulation activities (APS)
  • Support method qualification and transfer activities and participate in validation of microbiological methods commensurate with experience
  • Conduct Environmental Monitoring of controlled environments (ISO 5 production isolators, ISO 8 cleanrooms, CNC) including non-viable and viable air particulate, surface viables in a GMP manufacturing facility
  • Participate in EMPQ activities, assist in developing sampling plans and routine EM program for new cGMP cleanrooms and adjacent controlled areas as per ISO and other regulatory requirements
  • Conduct utilities monitoring of compressed gas systems including CDA, N2, CO2 (non-viable and viable air particulate) in a GMP manufacturing facility
  • Responsible for training of team members for GMP testing; effective communicator and deep technical expertise in key microbiology assays, to be able to share and communicate that knowledge through training of analysts
  • As a senior team member responsible for providing technical support and guidance to lab staff, assisting with troubleshooting and experimental design, leading investigational studies
  • Responsible for authoring trend reports for EM and utilities, also review reports that are generated and make conclusions as to any action required based on the data
  • Document results accurately in laboratory notebooks, LIMS, ELN, and batch records
  • Perform timely and accurate peer review of test results/reports, compile and review data to ensure accuracy and regulatory compliance
  • Collaborate with cross functional teams to develop and execute process improvement strategies ensuring alignment with organizational goals
  • Responsible for development and management of SOPs, forms, and method protocols/reports required to support compliant operation and testing conducted in the microbiology laboratory
  • Communicate effectively with management regarding road needs, task completion and issues related to QC Microbiology division
  • Investigate and document non-conforming events, OOS and EM excursions
  • Provide expertise in troubleshooting complex laboratory issues and demonstrating strong reasoning skills in support of ongoing laboratory investigations and change management processes
  • Support Quality Systems such as change control, deviation, CAPA, audits, quality metrics, etc.
  • Responsible for reviewing all data in compliance with applicable procedures and cGMP requirements as well as data integrity principles
  • Interface with contract testing laboratories a technical expert (e.g. microbial identification services)
  • Prepare COA/COT for testing performed
  • Participate in internal assessments and audits as required, supply quality control data necessary for regulatory submissions
  • Support equipment validation, calibration, maintenance, and troubleshooting
  • Maintain lab inventory, ensuring proper stock levels of media, reagents and consumables to support uninterrupted operations
  • Assist in maintaining a clean and safe laboratory environment, adhering to all safety and compliance requirements
  • Perform other duties as assigned
Desired Qualifications
  • Familiarity with rapid microbiology technology such as BAC-T, Nexgen-MCS is highly preferred
  • Sterility and endotoxin method qualification and transfer experience is highly preferred

Cellares develops and manufactures cell therapies in the biotechnology sector, operating as an Integrated Development and Manufacturing Organization (IDMO). This approach combines development and manufacturing processes in one facility, unlike traditional CDMOs. Their proprietary "Smart Factory" technology enhances productivity and reduces costs and failure rates. Cellares aims to provide efficient and cost-effective manufacturing services for cell therapies, making it a competitive choice in the industry.

Company Size

201-500

Company Stage

Series C

Total Funding

$355M

Headquarters

South San Francisco, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Bristol Myers Squibb secures $380M for CAR T cell therapy manufacturing.
  • Ossama Eissa's appointment as COO strengthens global Smart Factory expansion efforts.
  • Sony partnership enhances precision in cell therapy manufacturing with advanced flow cytometry.

What critics are saying

  • Emerging competition from companies like bluebird bio threatens Cellares' market share.
  • Rapid Smart Factory expansion may face logistical challenges in international markets.
  • Over-reliance on Bristol Myers Squibb partnership could be risky if dynamics change.

What makes Cellares unique

  • Cellares' Cell Shuttle offers 10x scalability over manual cell therapy manufacturing processes.
  • The Smart Factory technology integrates development and manufacturing, unlike traditional CDMOs.
  • Cell Q automates QC for up to 6,000 batches, reducing manual labor and costs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

3%

2 year growth

5%
RegMedNet
Apr 3rd, 2025
Cell therapy weekly: regulatory boost for automated cell therapy production platform

bluebird bio announced on 21 February 2025 that it had entered into a definitive agreement to be acquired global investment firms Carlyle (DC, USA) and SK Capital (NY, USA) for US$3.00 per share in cash, plus a contingent value right of $6.84 per share if certain sales targets are met.

ROI-NJ
Nov 13th, 2024
Cellares appoints former Novartis, Lonza and Legend Biopharma exec as COO

Cellares, a Bridgewater-based leader in automated cell therapy manufacturing, on Monday announced it appointed Ossama Eissa, former executive at Novartis, Lonza Biologics, and Legend Biotech, as chief operating officer.

ROI-NJ
Nov 13th, 2024
Cellares Appoints Former Novartis, Lonza And Legend Biopharma Exec As Coo

Cellares, a Bridgewater-based leader in automated cell therapy manufacturing, on Monday announced it appointed Ossama Eissa, former executive at Novartis, Lonza Biologics, and Legend Biotech, as chief operating officer.Eissa’s extensive experience will support the expansion of Cellares’ Smart Factory network in the United States, Europe, Japan and other international markets, addressing the challenges of scalability, cost, and quality that have long hindered patient access. Through these advancements, Cellares will work to ensure that life-saving treatments are accessible for oncology and autoimmune patients globally.This appointment strengthens the Cellares leadership team in a time of rapid global expansion of the company’s IDMO manufacturing services, in response to the growing global demand for cell therapy manufacturing capacity.Eissa brings more than 20 years of experience in pharmaceutical and biotech manufacturing.He formerly served as vice president and general manager at Legend Biotech, where he led the Raritan production site through the global launch of Carvykti, a CAR-T cell therapy.At Lonza Biologics, Eissa managed Global Strategic Projects, contributing significantly to the Cell and Gene Technologies Business Unit by boosting manufacturing efficiency and driving commercial scale-up. He also oversaw U.S. manufacturing operations at Novartis, scaling production and supporting regulatory approval for Kymriah, the first FDA-approved CAR-T cell therapy.“Joining Cellares is an opportunity to address one of the biggest challenges in healthcare today: making cell therapies accessible to all of those who need them,” Eissa said. “The mission aligns closely with my experience in scaling complex manufacturing systems to benefit patients directly. I’ve witnessed the profound impact these treatments have, and I’m committed to ensuring that we reach more patients, especially those facing cancer and autoimmune diseases, with the reliability and speed they deserve.”

BioProcess International
Sep 12th, 2024
Cellares and Sony partner to automate cell therapy manufacturing

Self-acclaimed integrated development and manufacturing organization (IDMO) Cellares has partnered with Sony Corporation, a technology firm focused on the field of flow cytometry, to integrate advanced flow cytometry-based cell analysis and sorting solutions into the Cellares Cell Shuttle platform.

Contract Pharma
Sep 3rd, 2024
Cellares Appoints CFO and General Counsel

Cellares, a leader in cell therapy manufacturing and an Integrated Development and Manufacturing Organization (IDMO), has appointed Justin McAnear as Chief Financial Officer (CFO) and Jonathan Butler as General Counsel and Corporate Secretary (GC).